The headset looks unremarkable enough—a sleek device that could pass for premium headphones. But Mave Health's founders insist what's happening beneath the surface matters more: mild electrical currents designed to stimulate specific brain regions, bundled into a 12-week program that the Bengaluru startup hopes will reshape how Indians approach mental health treatment.
Whether that vision holds up remains an open question. But Mave now has institutional backing to find out.
Blume Ventures revealed on October 29, 2025, while announcing the first close of its $175 million Fund V, that the neurotech startup had joined its portfolio. The investment amount went undisclosed—standard practice for early-stage deals in India, though perhaps more so when the science involved invites both curiosity and skepticism.
The Science and the Sell
Founded in 2023 by Dhawal Jain, Jai Sharma, and Aman Kumar, Mave is developing what it calls ARC: a wearable that deploys transcranial direct current stimulation, or tDCS. The technology isn't new—researchers have studied non-invasive brain stimulation for years—but consumer applications remain relatively nascent, especially in India.
Mave positions the device as part wellness tool, part structured program. Users pay for a three-month experience that layers therapy sessions, coaching, nutrition guidance, and fitness routines atop the neurostimulation itself. As of mid-2024, the company charged INR 20,000 monthly and was onboarding between 25 and 30 participants each month, operating on a cohort model that suggests careful scaling rather than blitz expansion.
The company claims clinical research backing from AIIMS and NIMHANS, India's most prominent medical institutions. Yet Mave markets ARC as a wellness device, sidestepping the Medical Device Rules 2017 that would trigger more rigorous regulatory oversight. That stands in contrast to competitors like Marbles Health, which pursued and secured approval from India's Central Drugs Standard Control Organisation for its tDCS device.
The distinction matters. Wellness claims carry less regulatory burden but also less clinical authority—a trade-off that may shape how doctors, patients, and investors assess Mave's long-term positioning.
Angel-Heavy Beginnings
Before Blume entered the picture, Mave had raised INR 6 crore (roughly $720,000) in an April 2024 pre-seed round led by All In Capital and Utsav Somani's iSeed. The investor list read like a who's who of India's startup ecosystem: Deepinder Goyal of Zomato, Kunal Shah of CRED, Gaurav Agarwal of Tata 1mg, Nandan Reddy of Swiggy, alongside the Bharat Founders Fund.
That roster signals something. These aren't investors chasing the next food delivery app or fintech play—they're individuals with the resources to take fliers on unconventional ideas. Whether Mave represents genuine breakthrough potential or simply an intriguing adjacency to their core interests is harder to parse.
What's clearer: the company imports its devices from Denmark and has been assembling clinical advisory support, with psychiatrists and medical professionals joining the team. A January 2026 launch timeline appeared on the company's LinkedIn profile, suggesting commercial rollout efforts were underway as the new year began.
Market Momentum, Market Questions
Timing-wise, Mave is riding two waves. India's mental health market hit approximately $20 billion in 2024 and could reach $27 billion by 2033, according to industry projections. Globally, neurostimulation devices represent a market forecast to balloon from around $6.7 billion in 2025 to somewhere between $13.9 billion and $25.2 billion by the early 2030s. The range in those estimates says something about how nascent and uncertain the category remains.
But markets don't guarantee success, particularly when patient education becomes its own obstacle. Convincing someone to strap on a brain-stimulating headset—and pay meaningfully for the privilege—requires trust that transcends slick marketing. Clinical evidence helps. So does word-of-mouth from early adopters. Regulatory clarity would help more.
Mave hasn't disclosed whether Blume's involvement represents a formal seed round, an extension of the pre-seed, or simply a strategic addition to the cap table. The size of Blume's check, the participation of other new investors, even the timing of when the deal actually closed—all remain unanswered. For a firm as transparent as Blume typically is, the quiet around this investment feels deliberate.
That opacity may reflect caution. Consumer neurotech in India doesn't have a roadmap yet; Mave is effectively drawing one. Founders and backers alike might reasonably prefer testing market response before making louder claims about what the device can and can't do.
What Comes Next
Mave has credible investors, experienced advisors, and a device that—at minimum—sits at the intersection of two growing markets. Whether the company can translate that foundation into a scalable, trusted mental health solution depends on variables that money alone won't solve: clinical outcomes that hold up under scrutiny, regulatory positioning that withstands evolving standards, and patient experiences that generate belief rather than doubt.
The founders have given themselves a narrow lane to navigate—skirting medical device regulation while invoking clinical credibility, building for scale while maintaining cohort intimacy, entering a space crowded with both promise and skepticism.
Blume's backing buys them time to figure out which lane widens into a real path forward. The rest remains to be written.
